← Back to screener

Trevi Therapeutics, Inc. TRVI

Rank #2270 · Nasdaq · $1.9B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
26.5
P/E
-40.2
P/B
23.32
ROE
-58.0%
Op. Margin
–%
Debt Ratio
14%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -40.2x, P/B 23.32x. Ranks in the top 81% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -58.0%. Ranks in the top 90% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 14%. Ranks in the top 11% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019–$-0.0B$-0.0B$-0.1B–-112
2020–$-0.0B$-0.0B$-0.1B–-155
2021–$-0.0B$-0.0B$0.1B–36
2022–$-0.0B$-0.0B$0.0B–78
2023–$-0.0B$-0.0B$0.0B–91
2024–$-0.0B$-0.0B$0.1B–6
2025–$-0.1B$-0.0B$0.1B–14

← See the full screener